Clinical Trials Using Mogamulizumab
Clinical trials are research studies that involve people. The clinical trials on this list are studying Mogamulizumab. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned after Treatment or Does Not Respond to Treatment
This phase Ib / II trial identifies the best dose and possible benefits and / or side effects of magrolimab when given in combination with mogamulizumab in treating patients with stage IB-IV mycosis fungoides or Sezary syndrome types of T-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Magrolimab and mogamulizumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Treatment with magrolimab in combination with mogamulizumab may stabilize cancer for longer period than the usual treatment in patients with relapsed / refractory T-cell lymphoma who have been previously treated.
Location: 5 locations
Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides
This phase Ib / II trial investigates the side effects of mogamulizumab and extracorporeal photopheresis and to see how well they work in treating patients with Sezary syndrome or mycosis fungoides. Mogamulizumab (a humanized antibody) binds to CCR4, a protein often found in high amounts on T-cell lymphoma cells. Binding to these cells may slow their growth, as well as mark them for attack by the immune system. Extracorporeal photopheresis (ECP) is a standard treatment for cancers that affects the skin, and may work by killing some lymphoma cells directly and by boosting the body’s immune response against other lymphoma cells. Giving mogamulizumab together with ECP may work better in treating patients with Sezary syndrome or mycosis fungoides compared to either therapy alone.
Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia
Mogamulizumab and Low-Dose Total Skin Electron Beam Therapy for the Treatment of Stage IB-IV Mycosis Fungoides and Sezary Syndrome
This phase II trial investigates how well mogamulizumab and low-dose total skin electron beam therapy work in treating patients with stage IB-IV mycosis fungoides and Sezary syndrome. Mycosis fungoides and Sezary syndrome are a subtype of cutaneous T-cell non-Hodgkin lymphoma. Mogamulizumab is an antibody that binds to a protein called CCR4. CCR4 is present on cancer cells in many patients with T-cell lymphoma. Mogamulizumab targets the T-cells with CCR4 on their surface and attempts to destroy them using the patient's immune system. Total skin electron beam therapy is a common treatment for clearing the skin disease in patients with cutaneous T-cell non-Hodgkin lymphoma. Yet total skin electron beam therapy alone does not address disease beyond the skin compartment and does not provide a meaningful benefit that lasts. Combining low-dose total skin electron beam therapy upfront with mogamulizumab may result in effective skin clearing and address systemic disease in patients with cutaneous T-cell non-Hodgkin lymphoma that may provide a more meaningful, lasting response than either therapy on its own.
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Microdevice for In Situ Candidate Drug Screening in Skin Lesions of T-Cell Lymphoma
This pilot trial studies the side effects and feasibility of microdevice for in situ candidate drug screening in skin lesions of T-cell lymphoma. Implanting and retrieving a microdevice that releases up to 19 drugs directly within a skin lesion may be a possible tool to evaluate the effectiveness of several approved cancer drugs against cutaneous T cell lymphoma or peripheral T cell lymphoma.
Location: 2 locations